Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.
Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.
No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.
GSK plc filed a Form 6-K disclosing the latest execution under its ongoing share repurchase programme.
- Shares repurchased: 491,972 ordinary shares on 03 July 2025.
- Price range: 1,380.50 p � 1,411.00 p; VWAP: 1,396.15 p.
- Programme history: Since the non-discretionary agreement with Merrill Lynch International on 04 June 2025, the company has bought back 9,493,915 shares.
- Treasury position: After this purchase GSK holds 227,628,298 shares in treasury, equal to 5.57 % of total voting rights.
- Shares outstanding (ex-treasury): 4,087,741,901.
- The repurchase volume on 03 July represents around 0.012 % of shares in issue, while cumulative June–July purchases equal roughly 0.23 %.
The filing provides the standard denominator for Disclosure Guidance and Transparency Rule (DTR) calculations and lists each individual trade executed on the London Stock Exchange. No other financial, operational or strategic information is included.
GSK plc has filed a Form 6-K to report its share capital and voting rights position as of 30 June 2025 under the UK Disclosure Guidance and Transparency Rule 5.6.1R. The company’s issued share capital totals 4,315,370,199 Ordinary Shares of 31 ¼ pence each, of which 226,172,571 shares are held in treasury and therefore do not carry voting rights. After adjusting for these treasury shares, the total number of voting rights currently exercisable amounts to 4,089,197,628. Shareholders should use this denominator when determining whether their holdings cross FCA disclosure thresholds. The notice is signed by Company Secretary Victoria Whyte on 1 July 2025 and provides an email address ([email protected]) for notifications.
GSK has reported a significant share buyback transaction on June 26, 2025. The company purchased 485,032 ordinary shares through Merrill Lynch International at prices ranging from 1,390.00p to 1,405.00p per share, with a volume-weighted average price of 1,397.83p.
Key transaction details:
- All purchases were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 225,206,623 shares in treasury
- Total voting rights now stand at 4,090,138,849
- Treasury shares represent 5.51% of voting rights
This purchase is part of GSK's ongoing buyback programme announced on June 4, 2025, under which the company has acquired 7,072,240 ordinary shares to date. The transaction demonstrates GSK's continued commitment to returning value to shareholders through its share repurchase strategy.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
